Drugs / Terlipressinum
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03352349 | Dec 2017 → Oct 2018 | portal hypertension | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Terlipressinum | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03352349 ↗ |
| Route | Intravenous | “given to patients intravenously” NCT03352349 ↗ |